Biotechnology companies Active Biotech (STO: ACTI) and NeoTX Therapeutics Ltd (NeoTX) on Monday announced the dosing of the first patient in its Phase 1b trial of naptumomab estafenatox (naptumomab, ANYARA) in combination with AstraZeneca's checkpoint inhibitor IMFINZI (durvalumab) for the treatment of advanced or metastatic solid tumours.
Reportedly, this study aims to establish the maximum tolerated dose in the dose-escalation phase 1b study before advancing to a phase 2 cohort expansion study.
This open-label, multicentre, dose-finding Phase 1b trial enrols patients with previously treated advanced or metastatic tumours. Patients will be treated with a combination of naptumomab and durvalumab.
Naptumumab (naptumomab estafenatox, ANYARA,) is a tumour targeting immunotherapy that enhances the ability of the immune system to recognise and kill the tumour.
The companies added that Naptumomab was licensed from Active Biotech to NeoTX Therapeutics Ltd in 2016. NeoTX is responsible for the global development and commercialisation of naptumomab for the treatment of cancer under the license agreement.
Active Biotech is focussed on neurodegenerative/inflammatory diseases and cancer, while NeoTX is a clinical-stage biopharmaceutical company dedicated to developing promising therapeutic candidates in the field of immuno-oncology.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007